About the Ypsomed Group
The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 800 employees.
Ypsomed Diabetes Care
With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9 % p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.
Financials
During the first semester of the business year 2020/21, we achieved a consolidated total turnover of CHF 199.3 million (previous year: CHF 190.6 million). This corresponds to a growth of 4.6 % and CHF 8.7 million compared with the previous year. The operating result amounted to CHF 8.3 million (previous year: CHF 9.0 million) and a net profit of CHF 6.5 million (previous year: CHF 7.6 million).
Financial key figures
(Unaudited Swiss GAAP FER figures) in thousand CHF
| 01 April 2020 – 30 Sept. 2020 |
in % | 01 April 2019 – 30 Sept. 2019 |
in % | |
|---|---|---|---|---|
| Sales of goods and services | 199 333 | 100.0 % | 190 622 | 100.0% |
| Cost of goods and services sold | – 152 015 | – 76.3 % | – 144 674 | – 75.9% |
| Gross profit | 47 318 | 23.7 % | 45 948 | 24.1% |
| Marketing and sales expenses | – 30 491 | – 15.3 % | – 32 860 | – 17.2 % |
| Administration expenses | – 10 434 | – 5.2 % | – 10 540 | – 5.5 % |
| Other operating income | 2 334 | 1.2 % | 7 049 | 3.7 % |
| Other operating expenses | – 385 | – 0.2 % | – 562 | – 0.3 % |
| Operating profit | 8 342 | 4.2 % | 9 035 | 4.7 % |
| Financial income | 3 608 | 1.8 % | 3 789 | 2.0 % |
| Financial expenses | – 4 320 | – 2.2 % | – 3 805 | – 2.0 % |
| Profit before income taxes | 7 630 | 3.8 % | 9 019 | 4.7 % |
| Income taxes | – 1 102 | – 0.6 % | – 1 416 | – 0.7 % |
| Net profit | 6 528 | 3.3 % | 7 603 | 4.0 % |
| Earnings per share (diluted and undiluted) in CHF |
0.52 | 0.60 | ||
| Operating profit | 8 342 | 9 035 | ||
| Depreciation and impairment of fixed assets | 15 698 | 13 413 | ||
| Amortisation and impairment of intangible assets | 9 793 | 9 301 | ||
| EBITDA 1 | 33 834 | 17.0 % | 31 749 | 16.7 % |
1 Operating profit before depreciation and amortisation.
